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Background: Hepatitis C virus (HCV) infection is common among prisoners, particularly those with a history of
injecting drug use (IDU). Incarcerated people who inject drugs frequently report high-risk injecting practices both in
prison and in the community. In spite of rising morbidity and mortality, utilisation of HCV-related services in
Australia has been persistently low. This study aimed to describe the incidence, prevalence and correlates of HCV
seropositivity in a large cohort of prisoners who have injected drugs, and to identify correlates of receiving
confirmation of active infection.
Methods: Data-linkage to a State-wide statutory notifiable diseases surveillance system was used to investigate the
incidence of notified HCV seropositivity, seroconversion and confirmed HCV infection in a cohort of 735 prisoners
with a history of IDU, over 14 years of follow up. Hepatitis C test results from prison medical records were used to
identify correlates of testing positive in prison.
Results: The crude incidence of HCV notification was 5.1 cases per 100 person-years. By the end of follow up,
55.1% of the cohort had been the subject of a HCV-related notification, and 47.4% of those tested in prison were
HCV seropositive. In multivariable analyses, injecting in prison was strongly associated with HCV seropositivity, as
was opioid use compared to injection of other drugs. The rate of reported diagnostic confirmation among those
with notified infections was very low, at 6.6 confirmations per 100 seropositive participants per year.
Conclusions: Injecting drugs in prison was strongly associated with HCV seropositivity, highlighting the need for
increased provision of services to mitigate the risk of transmission within prisons. Once identified as seropositive
through screening, people with a history of IDU and incarceration may not be promptly receiving diagnostic
services, which are necessary if they are to access treatment. Improving access to HCV-related services will be of
particular importance in the coming years, as HCV-related morbidity and mortality is increasing, and next generation
therapies are becoming more widely available.
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Hepatitis C virus (HCV) infection is a leading cause of
cirrhosis, liver failure and liver cancer worldwide [1,2]. The
most common risk factor for HCV exposure in high-income
countries is unsafe injecting drug use (IDU) [3,4], and due to
the close association between IDU and incarceration, HCV
infection is highly prevalent among prisoners [5,6].* Correspondence: kathryn.snow@unimelb.edu.au; s.kinner@unimelb.edu.au
1Melbourne School of Population and Global Health, University of
Melbourne, Melbourne, Australia
5School of Psychology, University of Queensland, Brisbane, Australia
Full list of author information is available at the end of the article
© 2014 Snow et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Surveys of prisoners in several Australian states have
recorded HCV seroprevalence in the range of 21–58% of
all prisoners [7-11], and 42–77% of prisoners report-
ing a history of IDU [7,8,11]. Comparable prevalence
estimates have been observed in prisoners who have
injected drugs in Scotland, Spain, and the United
States [6,12,13]. Seroconversion among HCV-naïve
prisoners who inject drugs has been observed at rates
between 5 and 34 cases per 100 person-years [8,9,14],
with the highest rates recorded among those continu-
ously incarcerated [5,15].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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risk of HCV transmission, due to the high prevalence of
HCV infection and inadequate harm reduction services
in many settings [5,9]. There are as yet no needle and syr-
inge exchange programs available in Australian prisons
[16], and opioid substitution treatment is not available to
men incarcerated in Queensland [17,18], the state from
which our participants were recruited. It is Queensland
Corrective Services policy that all prisoners are offered
testing for blood borne viruses including hepatitis C
during health assessments at reception, however they
may refuse testing [19].
Diagnosis of HCV infection is a two-step process. A
positive result upon serological testing indicates a history
of HCV exposure, and polymerase chain reaction (PCR)
for viral nucleic acid confirms the presence of active
(usually chronic) infection [20]. PCR confirmation may
be foregone under some circumstances, however it
forms a part of the standard diagnostic workup [20],
and as such receipt of this test may be considered an
indicator of engagement with care for HCV infection, a
precondition for accessing treatment. It has recently been
shown that a substantial proportion of seropositive individ-
uals in New York do not receive PCR testing [21].
The uptake of treatment for HCV infection has been
persistently low in Australia: despite the fact that treat-
ment is fully subsidised, fewer than 1% of an estimated
230,000 Australian residents living with chronic HCV
infection access treatment annually [3]. Access to HCV-
related services is limited by a lack of knowledge about
HCV infection in primary care [22], limited capacity
and long waiting lists at some hospital-based services
[23], and patient decisions to defer or forego potentially
arduous therapy [24].
It has previously been shown that referral to HCV-
related services among seropositive people who inject
drugs (PWID) in Australia is particularly suboptimal
[25]. As a substantial proportion of people living with
HCV infection pass through prisons each year [26],
identifying risk factors for non-engagement with diag-
nostic services in this population may assist efforts to
improve access to treatment.
The present study aimed to a) describe the incidence
of notified HCV seropositivity in a cohort of Australian
prisoners with a history of IDU, including seroconversion
among HCV-naïve participants after release from prison,
b) identify correlates of testing positive for HCV in prison,
and c) identify correlates of receiving notified PCR con-
firmation of active infection.
Methods
Cohort and study design
The Passports cohort consists of 1,325 individuals re-
cruited to a randomised controlled trial of a servicebrokerage intervention prior to release from seven
prisons in Queensland, Australia. Potentially eligible
participants were identified from prison records and
included sentenced prisoners within six weeks of expected
release from custody (full-time or parole) who were able
to provide informed, written consent. Women were over-
sampled to ensure sufficient numbers for stratified analyses.
According to data provided by Queensland Corrective
Services, the cohort is otherwise representative of the
population of people released from prisons in Queensland
over the same period [27].
Baseline data were collected via face-to-face adminis-
tration of a structured questionnaire in confidential in-
terviews between August 2008 and July 2010. The data
collection tool covered demographic characteristics;
incarceration history; general health, mental health
and health-related quality of life; alcohol, tobacco and
other drug use prior to and during incarceration, including
history of IDU; and other health risk behaviours. A detailed
description of the recruitment and interview process has
been published previously [27].
Measures and data sources
Variables of interest in this study were sex; age (categorised
by birth cohort); level of education (<10 vs. ≥10 years);
Indigenous status (yes/no); time since initiation of injecting;
lifetime injection of heroin (vs. injection of other drugs)
and history of opioid substation therapy (OST); history of
tattooing (vs. no tattoos); prior incarceration (juvenile and/
or adult vs. none); lifetime prison IDU (vs. community only);
and lifetime sharing of injecting equipment such as needles,
syringes, spoons or tourniquets (vs. no reported sharing).
In our cohort, injecting in prison was reported almost
exclusively by participants who also reported sharing
equipment in the community [8], making them a subset of
this larger group. To accommodate this, these two variables
were combined into one ordinal variable with 3 categories
(1: no prison IDU and no sharing in the community; 2:
sharing in the community without prison IDU; 3: sharing
in the community and prison IDU).
Outcomes of interest were HCV seropositivity and
PCR-confirmed active HCV infection. Clinical identification
of both HCV seropositivity and active HCV infection are
notifiable events in Australia, with reports made to state
health authorities. Each notification event appears in the
dataset as a separate record, including a personal unique
identifier, sex, diagnosis, type of test (serology or PCR) and
test date. Surveillance data were obtained via retrospective,
probabilistic record linkage to the Queensland Notifiable
Conditions Systems for the period from 1st January
1999 to 1st June 2013. Linkage was based on full name
(including all known aliases), sex, date of birth, and
postcodes of residence. The linkage procedure was
based on that used by the Western Australian Data Linkage
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censoring, data on deaths between recruitment and 31
May 2013 were obtained via probabilistic linkage to
the Australian National Death Index.
Of the original Passports cohort, seven (0.5%) participants
withheld consent for record linkage, and three (0.2%)
declined to answer questions regarding IDU at baseline
interview. Their data were not included in this study.
The final sample described here consists of 735 participants
who reported a history of IDU, representing 55.5% of
the entire Passports cohort. Among this sample, 419
participants had a record of a test for HCV antibodies
in prison. Results were available for 403 participants,
and these were extracted from their prison medical records
after their baseline interview.
Statistical methods
The incidence of HCV notification was calculated among
all those who had injected drugs. Participants estimated to
have initiated IDU after 1999 were considered at risk from
an estimated date of first IDU, based on self-reported age
at initiation. The rate of apparent seroconversion after re-
lease from prison was calculated in a subset of individuals
whose prison medical records included a negative test for
HCV in the year prior to their release. These participants
were deemed to be at risk from the date of their release
from prison, and were censored on the date of their first
notification for HCV, their date of death, or 1 June 2013,
whichever came first.
Logistic regression was used to estimate the association
between measured risk factors and a positive HCV test in
prison. Year of birth was highly correlated with time since
initiation of injecting; consequently, only time since initi-
ation was included in the model, as this is the more direct
measure of time at risk of HCV exposure. Interactions
between age, sex, time since initiation and opioid use
were explored and their impact on the multivariate
model assessed. No interactions were found to be sig-
nificant. Of the 403 participants with test results avail-
able, 4 did not answer all interview questions, resulting
in a final sample of 399 for this analysis.
In order to investigate the delay between positive
serological testing and diagnostic (PCR) testing, the
rate of notified PCR confirmation of active infection
was calculated among those with a record of notified
HCV seropositivity. As the outcome of interest was
the delay between detection of HCV antibodies and
PCR confirmation of active infection, 28 participants
whose first notification was based on PCR rather than
serological testing were excluded from PCR confirmation
analysis, providing a final sample of 377 participants for
this analysis. Follow-up time for each participant began
on the date of first notification for HCV seropositivity.
Censoring occurred at the test date for the first notifiedPCR confirmation, date of death, or 1 June 2013, whichever
came first.
Potential correlates of PCR confirmation were inves-
tigated using Cox regression. Due to the smaller number
of observations available for this analysis, continuous
variables were divided above and below the median value
to preserve statistical power, and the two higher-risk
injecting categories were combined into a single category
(sharing equipment and/or injecting in prison, vs. no
sharing equipment and no prison IDU).
Exposures and potential confounders of interest for both
analyses were identified during a review of the literature.
Possible causal relationships between these variables were
assessed using directed acyclic graphs, and this informed
the specification of the multivariate models. Both models
were specified in advance and included all variables identi-
fied as exposures and/or potential confounders. Age and
time since initiation were highly correlated, and were not
included in the same models: time since initiation was
included in the analysis of prison test results, as it is the
more direct measure of time at risk of HCV exposure,
while age was used in the PCR analysis as it is of higher
clinical relevance among people living with HCV infec-
tion. All statistical analyses were performed in Stata 13
(StataCorp LP, Texas, USA).
Ethics approval
Ethics approval for the study was granted by The University
of Queensland’s Behavioural and Social Sciences Ethical
Review Committee. Approval for linkage to data from
the National Death Index and the Queensland Notifiable
Conditions Systems were provided by the Australian
Institute of Health and Welfare Ethics Committee and the
Queensland Health Human Research Ethics Committee
respectively.
Results
The injecting cohort was predominantly young (median
age 29 years) and male (77.0%), with a median time since
initiation of IDU of 16 years. A large majority (86.7%)
had been incarcerated previously, and having injected drugs
in prison was reported by 285 participants (39.2%). The
majority of the sample (94.8%) reported having been tested
for HCV, and 405 (55.1%) had a record of a HCV-related
notification. Prison medical records indicated that 419
participants (60.2%) had been tested in prison; of the 403
participants for whom results were available, 191 (47.4%)
were seropositive.
The crude incidence of HCV notification in the cohort
between 1999 and mid 2013 was 5.1 per 100 person-years
(see Table 1). The incidence of seroconversion among the
77 individuals who were confirmed as HCV seronegative
in the year prior to release from prison was 5.5 per 100
person-years; the median time to first HCV notification











Injecting cohort 735 7,919 405 5.1 (4.6, 5.6)
Seroconversion
after release*
77 266 12 5.5 (3.1, 9.7)
PCR confirmation
after notification
377 1,968 130 6.6 (5.6, 7.8)
*Among participants who received a negative test result in prison in the year
prior to release.
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11 months.
In the multivariable analysis there was a strong associ-
ation between heroin injection and testing positive for
HCV in prison, particularly if a history of OST was also
reported (see Table 2). Sharing injecting equipment in the
community and injecting in prison were associated with in-
creased risk, as was greater time since initiation of injecting.
Women and people who had been incarcerated as juveniles
were substantially more likely to test positive.
Of the 377 participants with an initial HCV notifica-
tion based on serology, only 130 (34.5%) had a record in
the notification data for PCR confirmation of active in-
fection (see Table 3). The rate of PCR confirmation after
first HCV notification was low, at 6.6 confirmations per
100 seropositive participants per year (95% CI: 5.6, 7.8).
For the 130 participants with PCR confirmations, the me-
dian time between first notification and first confirmation
was 1 year, 11 months. Female sex was associated with a
higher rate of confirmation in univariable analysis, however
this effect was attenuated in the multivariable analysis. OnlyTable 2 Correlates of HCV seropositivity in injecting cohort w





Female (vs. male) 191 (21.8) 54
Indigenous (vs. non-indigenous) 91 (22.6) 40
Educated 10 years or more (vs. <10 years) 196 (48.6) 86
Injecting 10 years or more (vs. <10 years) 210 (52.2) 97
Injecting 20 years or more (vs. <10 years) 115 (28.6) 76
Heroin injection (vs. other drugs) 163 (40.8) 87
Heroin injection with OST (vs. other drugs) 86 (21.5) 66
Shared injecting equipment in community
(vs. no sharing, no prison IDU)
109 (27.1) 64
Injected in prison (vs. no sharing, no prison IDU) 156 (38.7) 96
Tattoos (vs. no tattoos) 340 (84.4) 17
Prior incarceration as adult only (vs. none) 209 (51.9) 99
Prior incarceration as juvenile (vs. none) 150 (37.2) 81juvenile incarceration remained significantly associated with
reduced PCR confirmation in the multivariable model.
Discussion
Incidence, prevalence and correlates of HCV exposure
At 47.4%, the prevalence of HCV seropositivity among
participants tested in prison is within the range previ-
ously reported among incarcerated Australians who have
injected drugs [7,11,26]. The crude incidence rate reported
here is not directly comparable to other cohorts, as the
retrospective component of this study meant that the
majority of follow-up time preceded incarceration. The
rate of seroconversion in the community after release
among those with a history of IDU was similar to that
reported in two comparable Australian cohorts of ex-
prisoners [14,29], and in a cohort of PWID continuously
incarcerated in a Spanish prison with a needle and syringe
exchange program [13]. However, it was substantially lower
than rates recorded among continuously incarcerated
PWID in New South Wales, where needle and syringe
exchange programs are not available [5,15]. As in other
studies, female participants were significantly more
likely to test positive for HCV in prison, and the ob-
served HCV seroprevalence of 61.3% among female
participants tested in prison is within the range previ-
ously reported among incarcerated Australian women
who inject drugs [7-9,26].
The high prevalence of methamphetamine injection
relative to heroin injection in Queensland has been re-
ported previously, as has a higher prevalence of HCV
exposure among recent heroin injectors relative to re-
cent methamphetamine injectors [26]. The increase in
risk of HCV seropositivity among heroin injectors







(61.4) 2.06 (1.27, 3.35) 2.74 (1.45, 5.18)
(44.0) 0.84 (0.53, 1.35) 0.76 (0.42, 1.36)
(43.4) 0.73 (0.49, 1.08) 0.79 (0.48, 1.29)
(46.2) 3.03 (1.66, 5.54) 2.83 (1.38, 5.78)
(66.1) 6.88 (3.55, 13.34) 4.54 (2.05, 10.1)
(53.4) 3.66 (2.25, 5.94) 1.95 (1.11, 3.43)
(76.7) 10.5 (5.64, 19.7) 4.13 (2.02, 8.42)
(58.7) 4.91 (2.83, 8.53) 3.19 (1.69, 6.04)
(61.5) 5.52 (3.30, 9.23) 3.57 (1.94, 6.57)
1 (50.3) 2.18 (1.23, 3.85) 1.38 (0.70, 4.98)
(47.4) 2.70 (1.30, 5.63) 2.05 (0.84, 4.98)
(54.0) 3.52 (1.66, 7.49) 3.07 (1.20, 7.88)
Table 3 Correlates of PCR confirmation in HCV seropositive participants






Total 1,968 130 6.6 -
Female (vs. male) 418 41 9.8 1.65 (1.14, 2.39) 1.36 (0.91, 2.03)
Born <1979 (vs. 1979 or later) 984 55 5.6 0.81 (0.57, 1.15) 0.84 (0.59, 1.21)
Educated 10 years or more (vs. <10 years) 910 59 6.5 0.96 (0.68, 1.36) 0.88 (0.61, 1.27)
Indigenous (vs. non-indigenous) 440 31 7.1 1.08 (0.72, 1.61) 1.11 (0.72, 1.70)
Ever injected heroin (vs. only injected other drugs) 1,499 86 (33.6) 5.7 0.66 (0.45, 0.94) 0.68 (0.46, 1.00)
Higher risk injecting (vs. no sharing or prison IDU) 1,510 100 (35.8) 6.6 1.05 (0.70, 1.58) 1.21 (0.79, 1.86)
Previously incarcerated –adult only (vs. never) 1,018 73 (37.8) 7.2 0.59 (0.35, 1.00) 0.64 (0.37, 1.10)
Previously incarcerated –juvenile (vs. never) 817 39 (26.5) 4.8 0.40 (0.23, 0.70) 0.44 (0.24, 0.80)
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with a number of additional risk factors for HCV ex-
posure including prison IDU, sharing injecting equip-
ment in the community, and younger age at first IDU
(data not shown). That the increased risk of HCV ex-
posure was preserved after adjustment for these factors
may reflect variation in unmeasured behaviours such
as frequency of injecting, frequency of sharing inject-
ing equipment, and the number of people with whom
injecting equipment was shared.
This variation in unmeasured aspects of risky injecting
may also explain the observed association between a history
of OST and higher odds of HCV seropositivity, which has
been reported previously [5]; a history of OST may indicate
a higher level of heroin dependence, and consequently may
be associated with a history of more frequent or more pro-
longed risky injecting. In our sample, 86.2% of those with a
history of OST reported higher risk injecting practices
(sharing equipment and/or injecting in prison), compared
to 74.9% of heroin users with no history of OST, and 38.7%
of injectors of other drugs.
As in other studies [7,14,15], prison IDU stands out as
a key correlate of HCV exposure. Injecting in prisons
might be reduced if OST were available to all opioid-
dependent inmates; women in our cohort, who may have
access to OST while incarcerated in Queensland, were far
less likely to report having injected in prison than men
were (16.6% vs. 45.9%). The risk to those who do inject in
prison might be reduced if additional harm reduction
measures, such as needle and syringe exchange programs,
were available.
Incidence and correlates of PCR confirmation
Only one third (34.5%) of those with notified HCV
seropositivity subsequently appeared in the notification
data as having received PCR confirmation of active in-
fection, suggesting that at least half of those participants
living with chronic HCV infection may not have received
complete diagnostic assessments. If all those with notifiedHCV exposure received PCR testing to confirm their
current infection status within one year, assuming that
70-80% of those with notified HCV exposure went on
to develop chronic infection [6], the expected rate of
PCR confirmation would be no lower than 70 per 100
person years. The rate of confirmation observed in this
cohort is an order of magnitude lower, at 6.6 confirmations
per 100 seropositive participants per year.
The fact that older age was not associated with higher
rates of PCR confirmation is concerning, as this may in-
dicate that the presence of easily identifiable risk factors
for greater duration of chronic HCV infection is not
resulting in more attentive diagnostic follow-up in this
population. However, the statistical power available for
this analysis would have been limited by the low rate of
confirmation, which is sobering in itself.
Limitations
The passive nature of the surveillance system from which
our data on incidence were drawn may have led to under-
estimation of the true incidence of HCV infection and
seroconversion. Most previous studies in this population
have used active serosurveys, while the present study used
passively collected surveillance data to estimate incidence.
As a result, the incidence estimates may have been influ-
enced by the frequency of testing and the completeness of
reporting. Any lengthy delays between seroconversion,
testing and reporting would lead to an underestimate of
the true incidence of HCV infection in the cohort.
Likewise, if positive PCR results are reported less
consistently than positive antibody results, the incidence
of PCR confirmation will have been underestimated. The
strength of this data-linkage approach, however, is that
any participant might appear in the surveillance data. Out-
come ascertainment was not dependent on continued
contact with investigators or return to prison, which can
result in substantial and biased attrition [30].
Responses to questions regarding high-risk behaviour
may have been affected by recall bias; participants who
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likely than those who knew that they were seronegative to
report stigmatised, higher-risk injecting practices. This is
unfortunately an unavoidable limitation of studies concern-
ing stigmatised, illegal behaviour; ultimately, self-report is
often the only way to collect such information [31]. That
half of even our seronegative participants reported at least
one higher risk injecting practice, however, suggests that
this effect may not be very strong.
Strengths
To the best of our knowledge, this study documents the
incidence of HCV seropositivity in the largest cohort of
prisoners with a history of IDU yet described in the global
literature [32]. It is one of a small number of true cohorts
recruited in prison settings, as opposed to repeated cross-
sectional surveys of convenience samples, in which HCV
incidence has been documented. As far as we could ascer-
tain, this is the first cohort of people with a history of incar-
ceration in which the incidence of PCR confirmation in the
community has been documented.
Conclusions
HCV exposure is highly prevalent among incarcerated
PWID, and prisoners in Australia do not have access to
the full range of harm reduction measures which are
available to people who inject in the community [5,15].
There is on-going discussion of trialling a needle and
syringe exchange program in one prison in Australia
[16], however this has not yet been implemented. That
only 60% of participants who self-reported a history of
IDU had a test for HCV in their prison medical records
may indicate that increased efforts to provide testing are
also needed, provided that the right of prisoners to refuse
testing is respected. In addition, the current gaps in the
provision of OST to opioid dependent people incarcerated
in Australia should be addressed.
The low uptake of HCV treatment in Australia has
long been recognised as a public health issue [3,25,33],
and is becoming ever more pressing as the incidence of
primary liver cancer rises [34-36]. Our findings indicate
that clinical follow-up after detection of HCV antibodies
in people with a history of incarceration may be very poor.
A substantial proportion of people living with chronic
HCV infection pass through prisons each year [37], and
this provides an opportunity for intervention with a highly
marginalised group who may not otherwise access
HCV-related services [38].
Studies in other Australian settings have demonstrated
that providing HCV treatment in prisons is effective [38].
With next generation therapies now becoming available,
reduced treatment duration may make the provision of
therapy to prisoners feasible even for those serving short
sentences. In light of rising HCV-related morbidity andmortality in the community, increased efforts focusing on
both prevention and treatment are needed to protect in-
carcerated PWID from HCV infection and its potentially
fatal sequelae.
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